{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006202","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.140626+00:00","generated_at":"2026-06-03T04:14:10.231656+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ProMIS publishes study showing PMN310's superior oligomer selectivity vs other Aβ antibodies","bullets":["PMN310 displayed greatest selectivity for toxic soluble Aβ oligomers among tested antibodies.","PMN310 avoided binding to plaque and vascular deposits, potentially reducing ARIA-E and ARIA-H risks.","Weekly murine PMN310 dosing at 800 mg/kg for 26 weeks in AD mice showed no detectable brain hemorrhages.","Phase 1a study in healthy volunteers ongoing; initial safety/PK data expected mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006202","json":"https://secwatch.observer/filing/0001558370-24-006202.json","markdown":"https://secwatch.observer/filing/0001558370-24-006202.md","text":"https://secwatch.observer/filing/0001558370-24-006202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024006202/0001558370-24-006202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024006202/pmn-20240430x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:14:10.231656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}